Phaseline

Companies › A2 Biotherapeutics

A2 Biotherapeutics: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
A2B530
Logic-gated CAR T-cell targeting CEA; selective activation in HLA-A*02 negative cells
CEACAM5Phase 1Solid Tumor, AdultDec 2026
A2B543
Mesothelin-targeting logic-gated CAR T cell therapy
MSLNPhase 1Solid Tumor, AdultJun 2028
A2B694
Mesothelin-targeting logic-gated CAR T cell therapy
MSLNPhase 1Solid Tumor, AdultJun 2028
A2B395
Allogeneic logic-gated CAR T cells targeting EGFR with HLA-A*02 loss as kill-switch
EGFRPhase 1Solid Tumor, AdultMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05736731A2B530Phase 1Solid Tumor, AdultOncologyDec 2026
NCT06051695A2B694Phase 1Solid Tumor, AdultOncologyJun 2028
NCT06051695A2B543Phase 1Solid Tumor, AdultOncologyJun 2028
NCT06682793A2B395Phase 1Solid Tumor, AdultOncologyMar 2029

Targets

MSLN (2) CEACAM5 (1) EGFR (1)

Companies with the same targets

Beijing Biotech AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Chongqing Precision Biotech Merck KGaA Genmab Pfizer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.